MX2013007067A - Anticuerpos anti-il-18 y sus usos. - Google Patents
Anticuerpos anti-il-18 y sus usos.Info
- Publication number
- MX2013007067A MX2013007067A MX2013007067A MX2013007067A MX2013007067A MX 2013007067 A MX2013007067 A MX 2013007067A MX 2013007067 A MX2013007067 A MX 2013007067A MX 2013007067 A MX2013007067 A MX 2013007067A MX 2013007067 A MX2013007067 A MX 2013007067A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- humanized
- conjugates
- interleukin
- diagnosing
- Prior art date
Links
- 102000003810 Interleukin-18 Human genes 0.000 abstract 2
- 108090000171 Interleukin-18 Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000009870 specific binding Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061424920P | 2010-12-20 | 2010-12-20 | |
| PCT/EP2011/073496 WO2012085015A1 (en) | 2010-12-20 | 2011-12-20 | Anti-il-18 antibodies and their uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013007067A true MX2013007067A (es) | 2013-11-01 |
Family
ID=45372272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013007067A MX2013007067A (es) | 2010-12-20 | 2011-12-20 | Anticuerpos anti-il-18 y sus usos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9255144B2 (OSRAM) |
| EP (1) | EP2655416A1 (OSRAM) |
| JP (1) | JP2014508511A (OSRAM) |
| KR (1) | KR20140003467A (OSRAM) |
| CN (1) | CN103339147A (OSRAM) |
| AU (2) | AU2011347354A1 (OSRAM) |
| BR (1) | BR112013015508B1 (OSRAM) |
| CA (1) | CA2822515C (OSRAM) |
| MX (1) | MX2013007067A (OSRAM) |
| RU (1) | RU2013133846A (OSRAM) |
| WO (1) | WO2012085015A1 (OSRAM) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200308A1 (ar) * | 2012-09-07 | 2017-06-16 | Novartis Ag | جزيئات إرتباط il-18 |
| JP6467225B2 (ja) * | 2012-11-21 | 2019-02-06 | Ｋｍバイオロジクス株式会社 | 新規なヒト抗ｉｌ−１８抗体 |
| ES2892923T3 (es) | 2013-09-05 | 2022-02-07 | Ab2 Bio Sa | Proteína de unión a IL-18 (IL-18BP) en enfermedades inflamatorias |
| WO2015160795A1 (en) * | 2014-04-14 | 2015-10-22 | The Regents Of The University Of California | Compositions and methods for treating inflammation |
| EP3265807A1 (en) * | 2015-03-05 | 2018-01-10 | AB2 Bio SA | Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases |
| PT3592384T (pt) | 2017-03-09 | 2025-10-01 | Mab Discovery Gmbh | Anticorpos que se ligam especificamente ao il-1r7 humano |
| WO2019213686A1 (en) * | 2018-05-10 | 2019-11-14 | The Council Of The Queensland Institute Of Medical Research | Therapeutic compositions and uses therefor |
| JP6892180B2 (ja) | 2018-12-03 | 2021-06-23 | 株式会社ｍＡｂＰｒｏｔｅｉｎ | 活性型インターロイキン−１８タンパク質のネオエピトープを認識する抗体、及びその応用 |
| CN109870570A (zh) * | 2018-12-29 | 2019-06-11 | 广东云天抗体生物科技有限公司 | 一种检测猴il-18的酶联免疫试剂盒 |
| GB202007404D0 (en) | 2020-05-19 | 2020-07-01 | Nasser Syed Muhammad Tahir | Treatment for viral respiratory infections |
| JP2023528455A (ja) * | 2020-06-01 | 2023-07-04 | アバロ・セラピューティクス・インコーポレーテッド | Ｉｌ－１８に対する抗体を伴う方法および処置 |
| CN112415191A (zh) * | 2020-11-06 | 2021-02-26 | 郑州人福博赛生物技术有限责任公司 | 一种白细胞三烯检测试剂盒 |
| EP4371573A4 (en) | 2021-07-13 | 2025-08-20 | National Univ Corporation Tokai National Higher Education And Research System | MEDICINAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE |
| WO2023067348A1 (en) | 2021-10-21 | 2023-04-27 | Biosirius Ltd | Treatment for virally-induced pneumonia |
| MX2024007616A (es) * | 2021-12-20 | 2024-09-04 | Avalo Therapeutics Inc | Métodos y tratamiento para la enfermedad de still de inicio en la edad adulta y la artritis idiopática juvenil de inicio sistemico que implica anticuerpos contra il-18. |
| MX2024011278A (es) | 2022-03-15 | 2024-09-25 | Compugen Ltd | Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer. |
| CN116236560A (zh) * | 2022-12-13 | 2023-06-09 | 华中科技大学同济医学院附属同济医院 | 人白细胞介素-37b在制备治疗鼻息肉的药品中的应用 |
| WO2024261470A1 (en) | 2023-06-20 | 2024-12-26 | Apollo Ap43 Limited | Anti-il-18 antibody therapy for treating atopic dermatitis |
| TW202515608A (zh) | 2023-06-26 | 2025-04-16 | 以色列商坎布根有限公司 | Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US565332A (en) | 1896-08-04 | Toy for making soap-bubbles | ||
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| US4424200A (en) | 1979-05-14 | 1984-01-03 | Nuc Med Inc. | Method for radiolabeling proteins with technetium-99m |
| US4479930A (en) | 1982-07-26 | 1984-10-30 | Trustees Of The University Of Massachusetts | Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5185243A (en) | 1988-08-25 | 1993-02-09 | Syntex (U.S.A.) Inc. | Method for detection of specific nucleic acid sequences |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| GB9206318D0 (en) | 1992-03-24 | 1992-05-06 | Cambridge Antibody Tech | Binding substances |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6492160B1 (en) | 1991-05-15 | 2002-12-10 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5962255A (en) | 1992-03-24 | 1999-10-05 | Cambridge Antibody Technology Limited | Methods for producing recombinant vectors |
| DE69230142T2 (de) | 1991-05-15 | 2000-03-09 | Cambridge Antibody Technology Ltd. | Verfahren zur herstellung von spezifischen bindungspaargliedern |
| US6225447B1 (en) | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5872215A (en) | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
| ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| PL194689B1 (pl) | 1996-02-13 | 2007-06-29 | Astrazeneca Uk Ltd | Pochodne chinazoliny, ich kompozycje farmaceutyczne oraz ich zastosowania |
| EP0885198B1 (en) | 1996-03-05 | 2001-12-19 | AstraZeneca AB | 4-anilinoquinazoline derivatives |
| US5814468A (en) | 1996-03-27 | 1998-09-29 | Coulter International Corp. | Methods of enumerating receptor molecules for specific binding partners on formed bodies and in solution |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| CA2276216A1 (en) * | 1998-06-24 | 1999-12-24 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | An artificial peptide capable of neutralizing the biological activity of interleukin-18 |
| ATE439592T1 (de) | 1998-12-10 | 2009-08-15 | Bristol Myers Squibb Co | Proteingerüste für antikörper-nachahmer und andere bindende proteine |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| AR022952A1 (es) | 1999-03-19 | 2002-09-04 | Smithkline Beecham Corp | ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL |
| HUP0300423A3 (en) * | 2000-02-10 | 2008-07-28 | Abbott Lab | Antibodies that bind human interleukin-18 and methods of making and using |
| EP1268766B1 (en) | 2000-03-31 | 2005-11-30 | Cambridge Antibody Technology Limited | Improvements to ribosome display |
| EP1289952A1 (en) | 2000-05-31 | 2003-03-12 | AstraZeneca AB | Indole derivatives with vascular damaging activity |
| WO2002008213A1 (en) | 2000-07-07 | 2002-01-31 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as angiogenesis inhibitors |
| CN1255391C (zh) | 2000-07-07 | 2006-05-10 | 安吉奥金尼药品有限公司 | 作为血管破坏剂的colchinol衍生物 |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| JP4134166B2 (ja) | 2003-04-30 | 2008-08-13 | 独立行政法人科学技術振興機構 | ヒト抗ヒトインターロイキン−１８抗体およびその断片、並びにそれらの利用方法 |
| US20050100965A1 (en) * | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
| US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
| EP2028193B1 (en) | 2005-01-05 | 2012-03-07 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions |
| GB0500099D0 (en) | 2005-01-05 | 2005-02-09 | Cambridge Antibody Tech | Methods and means relating to protein variants |
| EP2604628A3 (en) * | 2007-12-21 | 2013-08-21 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4R) - 173 |
| US20090202557A1 (en) * | 2008-01-30 | 2009-08-13 | Argiriadi Maria A | Compositions and methods for crystallizing antibody fragments |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
-
2011
- 2011-12-20 JP JP2013545325A patent/JP2014508511A/ja active Pending
- 2011-12-20 BR BR112013015508-6A patent/BR112013015508B1/pt active IP Right Grant
- 2011-12-20 US US13/993,537 patent/US9255144B2/en active Active
- 2011-12-20 KR KR1020137018576A patent/KR20140003467A/ko not_active Withdrawn
- 2011-12-20 CA CA2822515A patent/CA2822515C/en active Active
- 2011-12-20 EP EP11799104.2A patent/EP2655416A1/en not_active Withdrawn
- 2011-12-20 CN CN2011800612426A patent/CN103339147A/zh active Pending
- 2011-12-20 AU AU2011347354A patent/AU2011347354A1/en not_active Abandoned
- 2011-12-20 WO PCT/EP2011/073496 patent/WO2012085015A1/en not_active Ceased
- 2011-12-20 MX MX2013007067A patent/MX2013007067A/es not_active Application Discontinuation
- 2011-12-20 RU RU2013133846/10A patent/RU2013133846A/ru not_active Application Discontinuation
-
2017
- 2017-03-06 AU AU2017201512A patent/AU2017201512A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2013133846A (ru) | 2015-01-27 |
| US20140004128A1 (en) | 2014-01-02 |
| BR112013015508A2 (pt) | 2016-10-11 |
| CN103339147A (zh) | 2013-10-02 |
| US9255144B2 (en) | 2016-02-09 |
| WO2012085015A1 (en) | 2012-06-28 |
| CA2822515C (en) | 2023-04-25 |
| AU2017201512A1 (en) | 2017-03-23 |
| KR20140003467A (ko) | 2014-01-09 |
| CA2822515A1 (en) | 2012-06-28 |
| AU2011347354A1 (en) | 2013-08-01 |
| WO2012085015A9 (en) | 2013-06-27 |
| BR112013015508B1 (pt) | 2022-04-05 |
| JP2014508511A (ja) | 2014-04-10 |
| EP2655416A1 (en) | 2013-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013007067A (es) | Anticuerpos anti-il-18 y sus usos. | |
| MX357193B (es) | Moleculas de union anti-alfa sinucleina. | |
| MX350200B (es) | Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74. | |
| SG184310A1 (en) | Antibodies that bind human cd27 and uses thereof | |
| TN2011000528A1 (en) | Compositions and methods for antibodies targeting complement protein c3b | |
| MX338754B (es) | Anticuerpos humanos contra el factor tisular. | |
| PH12012501793B1 (en) | Monoclonal antibodies against c-met | |
| PH12013500810B1 (en) | Anti-il-23 antibodies | |
| JOP20210044A1 (ar) | الأجسام المضادة لـ cd38 | |
| WO2009083009A3 (en) | Monoclonal antibodies against cd32b | |
| AU2018256498A1 (en) | Antibodies to amyloid beta | |
| MX2010010387A (es) | Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos. | |
| MX2009008430A (es) | Anticuerpos anti-robo4 y sus usos. | |
| PH12014502406B1 (en) | Anti-il-23p19 antibodies | |
| PH12014501108A1 (en) | Anti-il-36r antibodies | |
| MX2010005022A (es) | Anticuerpos que unen celulas dendriticas y epiteliales 205 (dec-205) humanas. | |
| EP4269563A3 (en) | Anti-gd2 antibodies | |
| NZ728016A (en) | Novel modulators and methods of use | |
| SG178886A1 (en) | Humanized anti-cdcp1 antibodies | |
| JO3437B1 (ar) | أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها | |
| WO2015001013A3 (en) | Human anti-ifn-alpha antibodies | |
| EP2749570A3 (en) | Staphylococcus aureus specific human recombinant polyclonal antibodies and uses thereof | |
| TN2012000151A1 (en) | Chimeric antibodies specific for cd151 and use thereof in the treatment of cancer | |
| PH12013501424B1 (en) | Anti-cd38 antibodies | |
| TN2013000265A1 (en) | Anti-cd38 antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |